Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.91
CRIS's Cash to Debt is ranked higher than
61% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CRIS: 1.91 )
CRIS' s 10-Year Cash to Debt Range
Min: 1.86   Max: No Debt
Current: 1.91

Equity to Asset 0.56
CRIS's Equity to Asset is ranked higher than
64% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRIS: 0.56 )
CRIS' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.93
Current: 0.56

0.3
0.93
F-Score: 3
Z-Score: -9.44
M-Score: -1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -62.76
CRIS's Operating margin (%) is ranked higher than
71% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. CRIS: -62.76 )
CRIS' s 10-Year Operating margin (%) Range
Min: -6639.83   Max: -35.24
Current: -62.76

-6639.83
-35.24
Net-margin (%) -82.14
CRIS's Net-margin (%) is ranked higher than
69% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. CRIS: -82.14 )
CRIS' s 10-Year Net-margin (%) Range
Min: -35140.52   Max: -27.72
Current: -82.14

-35140.52
-27.72
ROE (%) -27.28
CRIS's ROE (%) is ranked higher than
68% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. CRIS: -27.28 )
CRIS' s 10-Year ROE (%) Range
Min: -443.91   Max: -9.74
Current: -27.28

-443.91
-9.74
ROA (%) -15.29
CRIS's ROA (%) is ranked higher than
72% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CRIS: -15.29 )
CRIS' s 10-Year ROA (%) Range
Min: -191.78   Max: -8.76
Current: -15.29

-191.78
-8.76
ROC (Joel Greenblatt) (%) -2111.21
CRIS's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CRIS: -2111.21 )
CRIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4290.32   Max: -228.83
Current: -2111.21

-4290.32
-228.83
Revenue Growth (%) -5.00
CRIS's Revenue Growth (%) is ranked higher than
70% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. CRIS: -5.00 )
CRIS' s 10-Year Revenue Growth (%) Range
Min: -40.5   Max: 72.9
Current: -5

-40.5
72.9
EBITDA Growth (%) 26.00
CRIS's EBITDA Growth (%) is ranked higher than
95% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. CRIS: 26.00 )
CRIS' s 10-Year EBITDA Growth (%) Range
Min: -49.4   Max: 26
Current: 26

-49.4
26
EPS Growth (%) 35.70
CRIS's EPS Growth (%) is ranked higher than
95% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. CRIS: 35.70 )
CRIS' s 10-Year EPS Growth (%) Range
Min: -74.5   Max: 35.7
Current: 35.7

-74.5
35.7
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRIS Guru Trades in Q1 2013

Steven Cohen 10,500 sh (New)
Jean-Marie Eveillard 16,777,656 sh (+0.61%)
» More
Q2 2013

CRIS Guru Trades in Q2 2013

Jean-Marie Eveillard 17,048,756 sh (+1.62%)
Steven Cohen Sold Out
» More
Q3 2013

CRIS Guru Trades in Q3 2013

Jean-Marie Eveillard 17,427,693 sh (+2.22%)
» More
Q4 2013

CRIS Guru Trades in Q4 2013

Jean-Marie Eveillard 17,889,009 sh (+2.65%)
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-03-31 Reduce -26.62%0.1%$1.98 - $3.28 $ 2.32-19%16612201
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.30
CRIS's P/B is ranked higher than
62% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CRIS: 4.30 )
CRIS' s 10-Year P/B Range
Min: 1.03   Max: 10.95
Current: 4.3

1.03
10.95
P/S 12.74
CRIS's P/S is ranked lower than
53% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CRIS: 12.74 )
CRIS' s 10-Year P/S Range
Min: 2.5   Max: 84.6
Current: 12.74

2.5
84.6
EV-to-EBIT 142.90
CRIS's EV-to-EBIT is ranked lower than
79% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CRIS: 142.90 )
CRIS' s 10-Year EV-to-EBIT Range
Min: 88.5   Max: 1121.1
Current: 142.9

88.5
1121.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.60
CRIS's Price/Net Cash is ranked higher than
55% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CRIS: 8.60 )
CRIS' s 10-Year Price/Net Cash Range
Min: 1.78   Max: 21.58
Current: 8.6

1.78
21.58
Price/Net Current Asset Value 8.30
CRIS's Price/Net Current Asset Value is ranked higher than
56% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CRIS: 8.30 )
CRIS' s 10-Year Price/Net Current Asset Value Range
Min: 1.78   Max: 20.04
Current: 8.3

1.78
20.04
Price/Tangible Book 5.50
CRIS's Price/Tangible Book is ranked higher than
58% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CRIS: 5.50 )
CRIS' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 11.7
Current: 5.5

1.63
11.7
Price/Median PS Value 0.90
CRIS's Price/Median PS Value is ranked higher than
74% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CRIS: 0.90 )
CRIS' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 9.84
Current: 0.9

0.12
9.84
Earnings Yield (Greenblatt) 0.70
CRIS's Earnings Yield (Greenblatt) is ranked lower than
69% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CRIS: 0.70 )
CRIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.1
Current: 0.7

0.1
1.1
Forward Rate of Return (Yacktman) -15.48
CRIS's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CRIS: -15.48 )
CRIS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -32.2   Max: -15.7
Current: -15.48

-32.2
-15.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CUS.Germany
Curis, Inc., was organized as a Delaware corporation in February 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a drug discovery and development company that is committed to leveraging its signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies. The Company's advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, which is also referred to as vismodegib, GDC-0449 and RG3616. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. Genentech is also conducting a separate phase II clinical trial of Erivedge in patients with operable nodular basal cell carcinoma, which is a less severe form of the disease and accounts for a significant percentage of the approximately two million BCCs diagnosed annually in the United States. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. In addition to the ongoing clinical trials that Genentech and Roche are conducting, Genentech and the National Cancer Institute, entered into a collaborative relationship that allows the NCI to study GDC-0449 in additional potential cancer indications. The Company's competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide